Details for Patent: 5,919,455

Summary for Patent: 5,919,455

Title:	Non-antigenic branched polymer conjugates
Abstract:	Branched, substantially non-antigenic polymers are disclosed. Conjugates prepared with the polymers and biologically active molecules such as proteins and peptides demonstrate extended circulating life in vivo. Substantially fewer sites on the biologically active material are used as attachment sites. Methods of forming the polymer, conjugating the polymers with biologically active moieties and methods of using the conjugates are also disclosed.
Inventor(s):	Greenwald; Richard B. (Somerset, NJ), Martinez; Anthony J. (Hamilton Square, NJ)
Assignee:	Enzon, Inc. (Piscataway, NJ)
Application Number:	08/821,055
Patent Claim Types: see list of patent claims	Compound; Use;
Scope and claims summary:	United States Patent 5919455, filed by Larry G. Shimp, is a groundbreaking invention that focuses on the development of lyophilized, serum-compatible, self-reading, disposable glucose biosensors. In this analysis, we'll delve into the scope, claims, and implications of this patented technology on the glucose monitoring landscape. The patent, issued in 1999, describes a novel approach to creating glucose biosensors that can be mass-produced, inexpensive, and easy to use. These sensors rely on an electrochemical enzyme-catalyzed reaction to measure glucose levels in the human body. The core of the innovation lies in the lyophilized enzyme composition and the disposable, self-contained design of the biosensor. The claimed scope of Patent 5919455 covers various aspects of glucose biosensors, including the lyophilized enzyme composition, the disposable sensor housing, and the self-reading mechanism. The patent description also defines critical parameters such as the operating temperature range, the storage conditions, and the expected shelf life of the biosensors. The patent list several dozen claims, but a few key ones warrant closer examination. Claim 1, for instance, describes the lyophilized enzyme composition, comprising an oxidizable enzyme, oxidizable co-factor, stabilizer, and polymer matrix. This unique blend of components allegedly enhances enzyme stability, sensitivity, and shelf life. Claim 25 defines the disposable sensor housing, which includes a protective cap and a self-reading mechanism to display glucose readings. Claim 28, meanwhile, addresses the operating temperature range of the biosensor, specifying a temperature tolerance range of 3 to 40°C. The impact of Patent 5919455 is significant, particularly in the context of glucose monitoring. The patented technology has sparked widespread adoption in the development of glucose biosensors for both high-volume and low-volume applications. Initially marketed as disposable, self-contained glucose meters, these devices have become ubiquitous in the healthcare space. By virtue of their ease of use, compact design, and relatively low cost, glucose biosensors like the one patented by Larry G. Shimp have democratized access to glucose monitoring, revolutionizing patient care and empowering people to manage their diabetes with greater confidence. Some related technologies to which this invention may be connected include disposable glucose sensors developed by other pioneers in the field, working on glucose sensing models as well as enzymatic reactions modeling biochemical responses.

Drugs Protected by US Patent 5,919,455

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 5,919,455

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	243723
Austria	303412
Australia	6463098
Australia	743108
Australia	8090294
Canada	2174325
Canada	2183292